Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Fill Finish Manufacturing
... at a CAGR of 8.6% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Medical Packaging
... CAGR of 5.5% over the analysis period 2024-2030. Medical Tools & Equipment, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$27.0 Billion by the end of ... Read More
-
Heart Failure Drugs
... at a CAGR of 12.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR The Heart Failure Drugs market in the U.S. ... Read More
-
Coenzyme Q10
... CAGR of 4.5% over the analysis period 2024-2030. Dietary Supplements, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$609.1 Million by the end of the analysis ... Read More
-
Global Maropitant Citrate Market Research Report 2025
... market for Maropitant Citrate is estimated to increase from $ 241.54 million in 2024 to reach $ 380.66 million by 2031, at a CAGR of 6.57% during the forecast period of 2025 through 2031. Asia-Pacific ... Read More
-
Global Maropitant Citrate API Market Research Report 2025
... American sales for Maropitant Citrate API are estimated to increase from 5,191 (Kg) in 2024 to reach 7,198 (Kg) by 2031, at a CAGR of 5.00 % during the forecast period of 2025 through 2031. ... Read More
-
Pharmaceutical Glass Ampoules
... at a CAGR of 6.4% over the analysis period 2024-2030. Straight Stem Ampoule, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$2.6 Billion by the end ... Read More
-
Alzheimer’s Disease Drugs
... at a CAGR of 5.6% over the analysis period 2024-2030. Donepezil, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$5.2 Billion by the end of the ... Read More
-
Pharmaceutical Packaging Equipment
... at a CAGR of 8.6% over the analysis period 2024-2030. Primary Packaging Equipment, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$16.7 Billion by the end ... Read More
-
Sanitary Valves
... CAGR of 3.4% over the analysis period 2024-2030. Control Valves, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$223.4 Million by the end of the analysis ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the end ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis period. ... Read More
-
Hyperlipidemia Drugs
... CAGR of 0.9% over the analysis period 2024-2030. Statins, one of the segments analyzed in the report, is expected to record a -7.3% CAGR and reach US$4.5 Billion by the end of the analysis period. ... Read More
-
Myeloproliferative Disorders Drugs
... at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion by ... Read More
-
Pharmaceutical Robots
... CAGR of 7.6% over the analysis period 2024-2030. Traditional Robots, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$224.1 Million by the end of the analysis ... Read More
-
Pharmaceutical Processing Seals
... at a CAGR of 8.2% over the analysis period 2024-2030. O-Rings, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.8 Billion by the end of the ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Triacetin
... 4.3% over the analysis period 2024-2030. Plasticizer, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$193.2 Million by the end of the analysis period. Growth in ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 Billion ... Read More
-
Bulk Paclitaxel
... CAGR of 8.5% over the analysis period 2024-2030. Semi-Synthetic Paclitaxel API, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$139.1 Million by the end of the ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the end ... Read More
-
Alpha-1 Antitrypsin Drugs
... at a CAGR of 9.6% over the analysis period 2024-2030. Prolastin C, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end of ... Read More
-
Antiemetic Drugs
... CAGR of 5.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.2 Billion by the end of the analysis period. ... Read More
-
Benign Prostatic Hyperplasia (BPH) Drugs
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Alpha-Blockers, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.4 Billion by ... Read More
Research Assistance
